Pharm'Up 
The long-awaited shield against Lyme disease is finally nearing the finish line. On March 23, 2026, Pfizer and Valneva released the results of their Phase 3 VALOR trial, providing the first major hope for a vaccine in over twenty years.
The experimental vaccine, known as PF-07307405, demonstrated a protective efficacy of up to 74.8% in preventing the disease. The study, which followed participants across the U.S., Canada, and Europe, found the treatment to be well-tolerated with no significant safety concerns.
A “Tick-Blocking” Innovation
What makes this vaccine unique is its “pre-transmission” defense. Instead of waiting for the bacteria to enter the human bloodstream, the vaccine’s antibodies are ingested by the tick during its blood meal. These antibodies then neutralize the Borrelia burgdorferi bacteria inside the tick’s gut, stopping the infection before it ever reaches the human host.
Addressing a Growing Threat
The timing of these results is critical. With the CDC estimating nearly 476,000 cases annually in the U.S. alone, and climate change pushing tick habitats into once-safe northern regions, the geographic risk of Lyme disease is expanding rapidly.
While the trial faced a minor statistical hurdle—accruing fewer cases than originally predicted for its primary goal—Pfizer’s Chief Vaccines Officer, Annaliesa Anderson, described the clinical evidence as “highly encouraging.”
The Path Forward
Pfizer and Valneva are now preparing to submit their findings to regulatory agencies. If approved, this “6-valent” vaccine would offer broad protection against the most common strains of the bacteria found across North America and Europe, providing a vital new tool for hikers, campers, and outdoor enthusiasts.
About the Author
